Maze Therapeutics initiates coverage with buy rating and $75 target price
MAZE•Canaccord Genuity initiated coverage of Maze Therapeutics with a buy rating and a $75 target price.
Related News
Meta apologizes after suspending 'No Kings' Instagram account
META•
Alpha Tau wins FDA approval to expand recurrent glioblastoma trial to 20 patients
DRTS•
Russia's Lavrov says Russia has no interest in volatility in energy prices
USO•
Research Frontiers says Gauzy financing enables restart of SPD-SmartGlass production
REFR•
Brinker International target price cut by UBS to $265 from $285
EAT•